Preview

Rational Pharmacotherapy in Cardiology

Advanced search

MAGNESIUM DEFICIENCY AND CARDIOVASCULAR DISEASES: TIME TO ACT

https://doi.org/10.20996/1819-6446-2014-10-1-99-105

Full Text:

Abstract

Progression of cardiovascular disease is often caused by a deficiency of magnesium in the human body. Magnesium belongs to the necessary vital macronutrients providing many physiological and pathological reactions and is involved in the constructive, energy, electrolyte metabolism. Correction of magnesium deficiency is realized using magnesium-containing drugs, for example magnesium orotate, having pleiotropic effects due to independent metabolic activity of orotic acid.

About the Author

E. I. Trisvetova
Belarusian State Medical University
Belarus


References

1. Gromov OA Torshin IY, KV Rudakov, et al. Lack of magnesium a significant risk factor comorbid conditions: results of a large-scale screening of magnesium status in the regions of Russia. Farmateka 2013; (6):116-29. Russian (ГромоваО.А., ТоршинИ.Ю., РудаковК.В., и др. Недостаточность магния – достоверный фактор риска коморбидных состояний: результаты крупномасштабного скрининга магниевого статуса в регионах России. Фарматека 2013;(6):116-29).

2. Ceremuzynski L., Gebalska J., Wolk R., Makowska E. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Intern Med 2000;247:78–86.

3. Moshfegh A., Goldman J., Cleveland L. What we eat in America, NHANES 2001–2002: Usual nutrient intakes from food compared to Dietary Reference Intakes. Washington: US Department of Agriculture, Agricultural Research Service; 2005.

4. Shilov A.M., Hosea A.O. Magnesium preparations (Magnerot) and cardiovascular disease in the practice of primary care. The Difficult Patient 2013;(12):12-7. Russian (Шилов А.М., Осия А.О. Препараты магния (Магнерот) и сердечно-сосудистые заболевания в практике врача первичного звена здравоохранения. Трудный Пациент 2013;(12);12-7).

5. Ma J., Folsom A.R., Melnick S.L., et alAssociations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995;48:927-40.

6. Altura B.M. Basic biochemistry and physiology of magnesium; A brief reviem. Magnesium and Farces Elements 1991;10:167-71.

7. Schimatchek H.F. Prevalence of hypomagnesaemia in an unselected German population of 16,000 individuals. Magnes Res 2001;14:283–90.

8. Hiraga H., Oshima T., Yoshimura M., et al. Abnormal platelet Ca2+ handling accompanied by increased cytosolic free Mg2+ in essential hypertension. Am J Physiol1998;275:R574-R579.

9. Kass L., Weekes J., Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. European Journal of Clinical Nutrition 2012;66(4):411-18.

10. Yezhov A.V., Pimenov L.T., Makarova M.I. et al. Exchange and other magnesium and clinical and functional characteristics in patients with stable coronary heart disease. Racional Pharmacother Card 2010;6(4):461-68. Russian (ЕжовА.В., ПименовЛ.Т., МакароваМ.И. и др. Обмен магния и клинико-функциональные характеристики у больных стабильной ишемической болезнью сердца. Рациональная Фармакотерапия в Кардиологии 2010;6(4):461-68).

11. Pokan R., Hofmann P., von Duvillard S.P., et al. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br J Sports Med 2006;40(9):773–78.

12. Shechter M., Sharir M., Labrador M.J. et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102: 2353 – 58.

13. Goldberger J.J., Cain M.E., Hohnloser S.H., et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008;118:1497–518.

14. Albert C.M., Chae C.U., Grodstein F., et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003;107:2096–101.

15. Reffelmann T., Ittermann T., Dorr M., et al.Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 2011;219:280-4.

16. Hu F.B., Stampfer M.J., Rimm E.B., et al. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. BMJ 1998;317:1341.

17. Peacock J.M., Ohira T., Post W., et al. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010;160:464–70.

18. K TeoK., YusufS., CollinsR., et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991;303:1499.

19. Woods K.L. Possible pharmacological actions of magnesium in acute myocardial infarction. Br J Clin Pharmacol 1991;32:3-10

20. Woods K.L., Fletcher S., Roffe C., et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Megnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-8.

21. Antman E.M. Magnesium in Acute Myocardial Infarction. Overview of Available Evidence. Am Heart J 1996;132: 487-95.

22. Adamopoulos C., Pitt B., Sui X., et al. Low serum magnesium and cardiovascular mortality in chronic heart failure: A propensity-matched study. Intern J Cardio 2009;136:270-7.

23. Keller P.K., Aronson R.S. The role of magnesium in cardiac arrhythmias. Prog Cardiovasc Dis 1990;32:433-48

24. Wang D.J., Yazawa K., Makita N., et al. Pharmacological targeting of the long QT mutant sodium channels. J Clin Invest 1997;99:1714–20.

25. Lloyd T., Iseri M.D., Fairshter R., et al. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J 1985;110:789-94.

26. Zehender M., Meinertz T., Just H. Magnesium deficiency and magnesium substitution. Effect on ventricular cardiac arrhythmias of various etiology. Herz 1997;22;Suppl 1:56–62.

27. Antman E.M. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomized controlled trial. Lancet 2002;360:1189-96.

28. Shechter M. Magnesium and cardiovascular system. Magnes Res 2010;23:60–72.

29. Stepura O.B, Martynow A.I. Magnesium orotate in sever congestive heart failure (MACH). Int J Cardiol 2009;134:145-47.

30. Svyiatov I.S., Shilov A.M., Maksimova L.A., et al The role of magnesium in preventing the syndrome of "reperfusion" in patients with AMI. TOP-medicine 1999;(3):29-30. Russian (Святов И.С., Шилов А.М., Максимова Л.А., и др. Роль препаратов магния в профилактике синдрома "реперфузии" у больных ОИМ. ТОП-медицина 1999;(3):29-30).

31. LouvetL., BüchelJ., Steppan S. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrology Dialysis 2013; 28(4): 869-78.

32. AfsarB., Elsurer R. The relationship between magnesium and ambulatory blood pressure, augmentation index, pulse wave velocity, total peripheral resistance, and cardiac output in essential hypertensive patients. Journal of the American Society of Hypertension 2014;1(8):28-35.

33. Hruby A., O'Donnell C.J., Jacques P.F., et al. Magnesium intake is inversely associated with coronary artery calcification: the framingham heart study. JACC Cardiovasc Imaging 2014; 7(1):59-69.

34. Rasmussen H.S., Aurup P., Goldstein K., et al. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. Arch Intern Med 1989; 149:1050-3.

35. Kao W.H., Folsom A.R., Nieto F.J., et al. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999;159:2151–9.

36. Hruby A., Meigs J.B., O'Donnell C.J., et al. Higher magnesium intake reduces risk of impaired glucose and insulin metabolism, and progression from prediabetes to diabetes in middle-aged Americans. Diabetes Care 2014;37(2): 419-27.

37. Dzeranova K.M., Avtandilov A.G., Vertkina N.V. Influence of magnesium on physical performance in young people with mitral valve prolapse: results of comparative study. Rational Pharmacother Card 2012, 8 (6) :752-5. Russian (Дзеранова К.М., Автандилов А.Г., Верткина Н.В. Влияние препаратов магния на физическую работоспособность у молодых людей с пролапсом митрального клапана: результаты несравнительного исследования. Рациональная Фармакотерапия в Кардиологии 2012;8(6):752-5)

38. Nurtdinova E.G., Zakirova A.N. Khairetdinova T.B. Comparative effect of monotherapy and combination therapy with magnesium and β-blocker for a primary mitral valve prolapse with heart rhythm disorders. Rational Pharmacother Card 2007 (3) :22-6. Russian (Нуртдинова Э.Г., Закирова А.Н., Хайретдинова Т.Б. Сравнительное влияние монотерапии и комбинированной терапии препаратом магния и β-адреноблокатором на течение первичного пролапса митрального клапана с нарушениями ритма сердца. Рациональная Фармакотерапия в Кардиологии 2007;(3):22-6)

39. Rosenfeldt F.L. Metabolic supplementation with orotic acid and magnesium orotate. Cardiovasc Drugs Ther 1998;12:Suppl 2:147–52.

40. Classen H.G. Magnesium orotate--experimental and clinical evidence. Rom J Intern Med 2004; 42(3):491-501.


For citation:


Trisvetova E.I. MAGNESIUM DEFICIENCY AND CARDIOVASCULAR DISEASES: TIME TO ACT. Rational Pharmacotherapy in Cardiology. 2014;10(1):99-105. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-1-99-105

Views: 531


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)